Use of big data in drug development for precision medicine

Rosa S. Kim, Nicolas Goossens, Yujin Hoshida

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Drug development has been a costly and lengthy process with an extremely low success rate and lack of consideration of individual diversity in drug response and toxicity. Over the past decade, an alternative “big data” approach has been expanding at an unprecedented pace based on the development of electronic databases of chemical substances, disease gene/protein targets, functional readouts, and clinical information covering inter-individual genetic variations and toxicities. This paradigm shift has enabled systematic, high-throughput, and accelerated identification of novel drugs or repurposed indications of existing drugs for pathogenic molecular aberrations specifically present in each individual patient. The exploding interest from the information technology and direct-to-consumer genetic testing industries has been further facilitating the use of big data to achieve personalized Precision Medicine. Here we overview currently available resources and discuss future prospects.

Original languageEnglish (US)
Pages (from-to)245-253
Number of pages9
JournalExpert Review of Precision Medicine and Drug Development
Volume1
Issue number3
DOIs
StatePublished - May 3 2016
Externally publishedYes

Fingerprint

Precision Medicine
Drug Repositioning
Chemical Databases
Genetic Testing
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Industry
Technology
Proteins
Direct-To-Consumer Screening and Testing

Keywords

  • Big data
  • drug development
  • high-throughput screen
  • in silico drug discovery
  • precision medicine

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Use of big data in drug development for precision medicine. / Kim, Rosa S.; Goossens, Nicolas; Hoshida, Yujin.

In: Expert Review of Precision Medicine and Drug Development, Vol. 1, No. 3, 03.05.2016, p. 245-253.

Research output: Contribution to journalArticle

@article{0431cca6fa764dc7be8b20b40ec25366,
title = "Use of big data in drug development for precision medicine",
abstract = "Drug development has been a costly and lengthy process with an extremely low success rate and lack of consideration of individual diversity in drug response and toxicity. Over the past decade, an alternative “big data” approach has been expanding at an unprecedented pace based on the development of electronic databases of chemical substances, disease gene/protein targets, functional readouts, and clinical information covering inter-individual genetic variations and toxicities. This paradigm shift has enabled systematic, high-throughput, and accelerated identification of novel drugs or repurposed indications of existing drugs for pathogenic molecular aberrations specifically present in each individual patient. The exploding interest from the information technology and direct-to-consumer genetic testing industries has been further facilitating the use of big data to achieve personalized Precision Medicine. Here we overview currently available resources and discuss future prospects.",
keywords = "Big data, drug development, high-throughput screen, in silico drug discovery, precision medicine",
author = "Kim, {Rosa S.} and Nicolas Goossens and Yujin Hoshida",
year = "2016",
month = "5",
day = "3",
doi = "10.1080/23808993.2016.1174062",
language = "English (US)",
volume = "1",
pages = "245--253",
journal = "Expert Review of Precision Medicine and Drug Development",
issn = "2380-8993",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Use of big data in drug development for precision medicine

AU - Kim, Rosa S.

AU - Goossens, Nicolas

AU - Hoshida, Yujin

PY - 2016/5/3

Y1 - 2016/5/3

N2 - Drug development has been a costly and lengthy process with an extremely low success rate and lack of consideration of individual diversity in drug response and toxicity. Over the past decade, an alternative “big data” approach has been expanding at an unprecedented pace based on the development of electronic databases of chemical substances, disease gene/protein targets, functional readouts, and clinical information covering inter-individual genetic variations and toxicities. This paradigm shift has enabled systematic, high-throughput, and accelerated identification of novel drugs or repurposed indications of existing drugs for pathogenic molecular aberrations specifically present in each individual patient. The exploding interest from the information technology and direct-to-consumer genetic testing industries has been further facilitating the use of big data to achieve personalized Precision Medicine. Here we overview currently available resources and discuss future prospects.

AB - Drug development has been a costly and lengthy process with an extremely low success rate and lack of consideration of individual diversity in drug response and toxicity. Over the past decade, an alternative “big data” approach has been expanding at an unprecedented pace based on the development of electronic databases of chemical substances, disease gene/protein targets, functional readouts, and clinical information covering inter-individual genetic variations and toxicities. This paradigm shift has enabled systematic, high-throughput, and accelerated identification of novel drugs or repurposed indications of existing drugs for pathogenic molecular aberrations specifically present in each individual patient. The exploding interest from the information technology and direct-to-consumer genetic testing industries has been further facilitating the use of big data to achieve personalized Precision Medicine. Here we overview currently available resources and discuss future prospects.

KW - Big data

KW - drug development

KW - high-throughput screen

KW - in silico drug discovery

KW - precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85013176031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013176031&partnerID=8YFLogxK

U2 - 10.1080/23808993.2016.1174062

DO - 10.1080/23808993.2016.1174062

M3 - Article

C2 - 27430024

AN - SCOPUS:85013176031

VL - 1

SP - 245

EP - 253

JO - Expert Review of Precision Medicine and Drug Development

JF - Expert Review of Precision Medicine and Drug Development

SN - 2380-8993

IS - 3

ER -